Precipio (NASDAQ:PRPO – Get Free Report) and AdaptHealth (NASDAQ:AHCO – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, dividends, profitability, institutional ownership, risk and analyst recommendations.
Volatility & Risk
Precipio has a beta of 1.32, suggesting that its stock price is 32% more volatile than the S&P 500. Comparatively, AdaptHealth has a beta of 1.39, suggesting that its stock price is 39% more volatile than the S&P 500.
Analyst Recommendations
This is a summary of recent ratings and recommmendations for Precipio and AdaptHealth, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Precipio | 1 | 0 | 0 | 0 | 1.00 |
| AdaptHealth | 1 | 1 | 7 | 0 | 2.67 |
Earnings and Valuation
This table compares Precipio and AdaptHealth”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Precipio | $24.05 million | 1.73 | -$360,000.00 | ($0.64) | -36.22 |
| AdaptHealth | $3.24 billion | 0.24 | -$70.79 million | ($1.71) | -3.30 |
Precipio has higher earnings, but lower revenue than AdaptHealth. Precipio is trading at a lower price-to-earnings ratio than AdaptHealth, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
10.4% of Precipio shares are held by institutional investors. Comparatively, 82.7% of AdaptHealth shares are held by institutional investors. 16.6% of Precipio shares are held by company insiders. Comparatively, 1.9% of AdaptHealth shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Profitability
This table compares Precipio and AdaptHealth’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Precipio | -4.47% | -8.49% | -5.75% |
| AdaptHealth | -7.07% | 3.36% | 1.16% |
Summary
AdaptHealth beats Precipio on 9 of the 14 factors compared between the two stocks.
About Precipio
Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; and HemeScreen, a suite of robust genetic diagnostic panels. It offers biomarker testing and clinical project services to bio-pharma customers. The company is based in New Haven, Connecticut.
About AdaptHealth
AdaptHealth Corp., together with its subsidiaries, sells home medical equipment (HME), medical supplies, and home and related services in the United States. The company provides sleep therapy equipment, supplies, and related services, such as CPAP and bi-PAP services to individuals suffering from obstructive sleep apnea; medical devices and supplies, including continuous glucose monitors and insulin pumps for the treatment of diabetes; HME to patients discharged from acute care and other facilities; oxygen and related chronic therapy services in the home; and other HME devices and supplies on behalf of chronically ill patients with wound care, urological, incontinence, ostomy, and nutritional supply needs. It also offers wheelchairs, hospital beds, oxygen concentrators, CPAP masks and related supplies, wound care supplies, diabetes management supplies, wheelchair cushion accessories, orthopedic bracing, breast pumps and supplies, walkers, commodes and canes, and nutritional and incontinence supplies. The company services beneficiaries of Medicare, Medicaid, and commercial insurance payors. The company is headquartered in Plymouth Meeting, Pennsylvania.
Receive News & Ratings for Precipio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Precipio and related companies with MarketBeat.com's FREE daily email newsletter.
